Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.
- Entitlement offer raises $2.2 million
- HMBD-002 abstracts accepted at AACR and ASCO
- Manufacture of clinical trial drug batch initiated
- Phase II trial preparation progressing
- Cash position improved post-capital raise
Capital Raise Fuels HMBD-002 Phase II Ambitions
Percheron Therapeutics (ASX:PER) has successfully closed a non-renounceable entitlement offer, raising approximately $2.2 million to advance its lead oncology candidate HMBD-002 into a planned phase II clinical trial in the second half of 2026. Eligible shareholders subscribed for two new shares for every five held at $0.005 each, with shortfall shares placed to new sophisticated and institutional investors. This injection of capital follows earlier announcements and reinforces the company’s commitment to progressing HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator VISTA, through clinical development. The entitlement offer included free attaching options exercisable at $0.01, providing additional potential upside for investors. The transaction was led by Blue Ocean Equities and Cygnet Capital, reflecting solid market support for Percheron's oncology program. This funding milestone builds on the company’s earlier $2.2M entitlement offer closure and sets the stage for upcoming clinical activity.
Scientific Exposure at Premier Oncology Conferences
Percheron has secured acceptance of abstracts related to HMBD-002 at two of the world’s most prestigious cancer research meetings. The American Association for Cancer Research (AACR) Annual Meeting in San Diego, scheduled for April 2026, will feature data principally from the recently completed phase I trial involving 48 patients with advanced cancer. Results demonstrated that HMBD-002 was generally safe and well tolerated, both as a standalone therapy and in combination with Keytruda (pembrolizumab), with some patients showing potential clinical benefit. Subsequently, a research collaboration with Brisbane’s QIMR Berghofer Institute has yielded preclinical data that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in May 2026. This collaboration, led by Professor Sudha Rao, aims to further elucidate HMBD-002’s biological activity and identify biomarkers for future clinical trials, underscoring Percheron’s strategy to leverage external expertise to support its pipeline. These scientific engagements not only validate the drug’s potential but also raise Percheron's profile among oncology researchers and investors. The company’s focus on clinical trial design and data dissemination follows earlier positive phase I findings and modular trial concepts highlighted in January.
Manufacturing Progress and Trial Preparation
Manufacture of a new batch of HMBD-002 drug substance commenced in March 2026 under the stewardship of Percheron’s licensor, Hummingbird Bioscience, at a specialist contract manufacturer in Asia. This manufacturing milestone fulfills a contractual obligation from the license agreement executed in June 2025 and is critical to supplying material for the upcoming phase II trial. Initial production phases completed in April 2026 met expected quality parameters, with final testing and release anticipated by June 2026. Subsequent vial filling and final drug product manufacture are scheduled for completion by August 2026. Meanwhile, Percheron is actively soliciting bids from international contract research organisations (CROs) to manage the phase II study and expects to announce its chosen partner soon. This preparation phase reflects a methodical approach to clinical development, balancing in-house expertise with external operational capacity.
Financial Position and Operating Cash Flow
At quarter-end 31 March 2026, Percheron reported a cash balance of $3.1 million, a reduction from $4.46 million the prior quarter, primarily due to $1.36 million in net operating outflows driven by research and development and corporate overheads. However, this figure predates the recent capital raise, which significantly bolsters the company’s financial runway beyond the 2.3 quarters previously forecast. The company’s R&D spend of $700,000 during the quarter underscores its continued investment in HMBD-002’s development. Payments to related parties, including directors’ fees and consulting, amounted to approximately $210,000 on commercial terms. The improved liquidity position post-entitlement offer places Percheron in a stronger position to execute its clinical and corporate plans without immediate funding concerns, complementing earlier half-year financial improvements reported in February.
Bottom Line?
Percheron’s recent capital raise and manufacturing progress set a clear path toward initiating its phase II trial, but final CRO selection and trial execution timelines remain key upcoming milestones.
Questions in the middle?
- Which contract research organisation will Percheron select to run the phase II trial?
- How will data presented at AACR and ASCO influence investor and clinical interest in HMBD-002?
- What are the potential impacts of manufacturing timelines on the planned trial start in 2H 2026?